Alnylam Pharmaceuticals (ALNY) opened 2026 on the back of a strong finish to last year, with Q4 2025 revenue of US$1.1b and basic EPS of US$1.41 supported by net income of US$186.4m as the company reported its latest numbers. Over the past few quarters, revenue has moved from US$593.2m in Q4 2024 to US$594.2m in Q1 2025, then to US$773.7m in Q2 2025 and US$1.25b in Q3 2025. Basic EPS shifted from a loss of US$0.65 in Q4 2024 to US$1.91 in Q3 2025 and US$1.41 in Q4 2025, reflecting a clear turn from losses to profitability. For investors, that path to positive EPS and higher net income puts margins at the center of this earnings story as you weigh how durable the recent profitability looks.

See our full analysis for Alnylam Pharmaceuticals.

With the headline figures set, the next step is to see how these results line up against the widely followed growth and risk narratives around Alnylam, and where those stories might need a rethink.

Profits Arrive While Product Engine Scales Up

• On a trailing basis, Alnylam reported US$3.7b in revenue and US$313.7m in net income, with basic EPS of US$2.39, alongside a pipeline that expanded to 16 Phase I, 5 Phase II and 7 Phase III programs plus 1 approved product by Q4 2025.
• Bulls argue that rapid AMVUTTRA uptake and a broadening RNAi pipeline can support structurally higher profitability, and the recent move from quarterly net losses in early 2025 to net income of US$186.4m by Q4 2025 heavily supports that view as long as the larger Phase III and approved-product base continues to translate into revenue.
  • The bullish narrative also leans on forecast revenue growth of about 16.5% a year and earnings growth of about 22.7% a year, which are both presented as ahead of the cited US market comparators in the data.
  • At the same time, the shift from a trailing twelve month loss of US$278.2m in Q4 2024 to a trailing profit of US$313.7m by Q4 2025 gives bulls concrete proof that the current commercial model can produce earnings rather than just top line growth.

Over the last year, bulls say this is the kind of earnings turn that can reshape how the market views Alnylam’s long term potential, and the detailed narrative walks through how that optimism ties back to the product ramp and pipeline breadth. 🐂 Alnylam Pharmaceuticals Bull Case

Premium P/E Versus DCF Upside

• The shares trade on a trailing P/E of 131.6x compared with a cited US Biotech industry average of 16.1x and a peer average of 41.7x, while the provided DCF fair value of US$610.25 sits well above the current share price of US$309.49 and the analyst price target of US$449.12.
• What stands out to cautious investors is that the stock’s rich P/E multiple sits alongside a DCF fair value that is very high relative to today’s price, so the bearish narrative that questions how much optimism is already in the valuation leans heavily on whether the forecast 22.7% earnings growth and 16.5% revenue growth can actually be delivered from this starting point.
  • Bears highlight that the P/E is several times higher than both industry and peers, so even if the DCF fair value of US$610.25 is eventually supported by outcomes, any wobble in growth expectations could matter a lot for how that multiple is viewed.
  • Supporters of the cautious view also point out that with the stock already trading above the cited analyst target of US$449.12 in the dataset, there is a clear gap between what the DCF model implies and what analysts collectively have in their target assumptions.

Skeptics frequently point to this valuation gap as a reason to stress test the assumptions behind both the bullish and bearish cases before relying too heavily on any single model or target. 🐻 Alnylam Pharmaceuticals Bear Case

From Loss-Making Quarters To Trailing Profitability

• Quarterly net income swung from losses of US$83.8m in Q4 2024 and US$57.5m in Q1 2025 to profits of US$251.1m in Q3 2025 and US$186.4m in Q4 2025, while trailing twelve month net income shifted from a loss of US$278.2m at Q4 2024 to a profit of US$313.7m at Q4 2025, alongside five year earnings growth of about 38.2% a year in the data.
• Consensus narrative views this move into profitability as an important proof point that the model can scale, yet it also flags that high R&D and SG&A, plus pricing pressures on AMVUTTRA and lower gross margins, could keep profit growth more uneven than the smooth revenue ramp implied by the roughly 16.5% revenue growth forecast.
  • The change from quarterly losses in early 2025 to positive EPS of US$1.91 in Q3 2025 and US$1.41 in Q4 2025 backs the idea that operating leverage is starting to show through, even with ongoing spending.
  • At the same time, the data notes declining gross margins on AMVUTTRA and continued heavy investment, which is why the balanced view still treats forecast earnings growth of 22.7% a year as something that needs ongoing execution, not a given.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Alnylam Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Does this mix of optimism and caution match your own read on Alnylam, or does the data point you somewhere else entirely? Take a closer look at the full risk and reward profile before you decide how it fits in your portfolio, starting with these 3 key rewards and 1 important warning sign.

See What Else Is Out There

Alnylam’s rich 131.6x P/E, margin pressures and reliance on ambitious 22.7% earnings growth forecasts leave room for valuation and execution risk.

If that level of uncertainty feels high for your comfort, compare it with companies screened for steadier profiles and stronger downside protection using our 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.